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University College London, Hampstead Campus, London NW3 2PF, UKObjective. The formation of an endothelial cell layer on the luminal surface of cardiovascular devices, especially bypass
grafts, is an important attribute in order to improve their patency. Endothelial progenitor cells (EPCs) have a potential role
in the endothelialisation of bypass grafts. We hypothesised that a novel approach to improve endothelialisation of bypass
grafts by EPCs would be the creation on the graft lumen of a microenvironment that supports EPC adhesion and
differentiation.
Methods. A new generation of nanocomposite based on silsesquioxane in the form of polyhedral oligomeric silsesquioxane
(POSS) nanocages which incorporate bioactive peptides (RGD) was made into sheets. Peripheral blood mononuclear cells
(PBMCs) containing EPCs isolated from six consenting young, healthy, adult volunteers were then plated both on (1) sheets
of the nanocomposite with the bioactive peptide, (2) sheets of the nanocomposite without the bioactive peptide, (3) culture
dishes as control and then cultured in presence of vascular endothelial growth factor (VEGF). Confirmation of endothelial
and EPCs markers was carried out using fluorescence-activated cell sorter (FACS) analysis, reverse transcription
polymerase chain reaction (RT-PCR) and immunostaining.
Results. One to two percent of PBMCs expressed CD34 as determined by FACS analysis. Cells were demonstrated to
express mRNA for the EPC markers CD34, platelet-endothelial cell adhesion molecule-1 (CD31), CD133 and vascular
endothelial growth factor receptor-2(FlK-1/KDR). Endothelial cell-colony forming units were formed between day 5 and day
7 after plating. Colonies were confirmed to be endothelial like cells by immunostaining. There were significantly greater
numbers of EPC colonies on the bioactive nanocomposites as compared to the nanocomposite alone and the uncoated dishes.
Conclusion. We report a new nanocomposite based biomaterial that has been demonstrated, in vitro, to promote
endothelialisation from PBMCs containing EPCs.Keywords: Nanocomposite; Tissue engineering; Stem cells; Endothelial progenitor cells; Bypass graft; Peptides; Vascular,
RGD, silsesquioxane.Introduction
Bypass grafts commonly are utilised for the treatment
of coronary or peripheral atherosclerosis, principally
using autogenous tissue. In 30–50% bypass patients,
all viable autologous tissue has already been used;1
under these circumstances synthetic prostheses are
employed. The current clinical prosthetic conduits arewarded The Young Vascular Surgeons’ prize at ESVS
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However, patency at 5 years is only 40–50% when
used to bypass to the proximal popliteal artery and
20% at 3 years when used for infra-popliteal bypass.2
To improve the patency rate such prostheses have
been seeded with endothelial cells using a two-stage
procedure.3 Two-stage seeding requires the harvesting
of endothelial cells from a vein biopsy, followed by
culturing/amplification for 2–4 weeks and then
seeding onto an ePTFE graft coated with the synthetic
peptide arginine-glycine-aspartic acid (RGD) and
fibrin. Clinical trials using endothelialised PTFE grafts
for femoro-popliteal bypass have been promising.Eur J Vasc Endovasc Surg 32, 76–83 (2006)
doi:10.1016/j.ejvs.2005.11.034, available online at http://www.sciencedirect.com onved.
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lialised PTFE grafts to controls, Zilla and colleagues
reported 5-year patency rates of 73.8% as compared to
31.3% in control(s).4 In a more recent paper,5 they
reported the results of 153 such endothelialised grafts
with a primary patency of 62.8% at 7 years.
Interestingly, this represented a patency rate of 70.8%
for bypass to vessels below the knee and 60% for those
above knee. However, such surgery is limited to a few
specialised centres with the necessary cell culture
facilities, technicians and bioreactors.
The discovery that vascular endothelial ‘stem cells’
or progenitor cells (EPC) exist,6 even in patients
suffering from cardiovascular disease, has led to
interest in their use in tissue engineering. The relative
ease of isolating these cells and their capacity to be
expanded in culture, up to as many as 1000 doublings,
whilst retaining their capacity to differentiate7 these
studies make EPC an interesting cell type for use in
tissue engineering. Increasing evidence indicates that
EPC have the potential to differentiate into mature
endothelial cells and contribute to the process of
endothelium repair, as they can home to specific sites
in response to endothelial injury, where they can
divide.8
The number of circulating EPC increase in response
to local ischaemia,9 statins,10 oestrogen,11 erythropoie-
tin12 and vascular endothelial growth factor (VEGF).
There is a rapid mobilisation of EPCs after burn injury
and surgical manipulation.13 Raised EPCs can be
detected in the circulation 6 h after injury and by
24 h EPCs constitute 12% of total circulating mono-
nuclear blood cells.14
EPCs have been differentiated into endothelial cells
in vitro and incorporated into sites of neovascularisa-
tion in vivo. EPCs show less plasticity and demonstrate
less capacity for self-renewal than earlier stem cells,
but retain the ability to differentiate into several cell
types. EPC differentiation in vitro is dependent on
culture conditions. VEGF and fibronectin are reported
to promote the differentiation of EPC into endothelial
cells.15 EPC are a heterogeneous groups of cells and
the exact definitions of all cells with endothelial
progenitor potential are still elusive.16 Several different
types of cells have been defined as EPC. (1) CD14
expressing monocytes/macrophages and mostly
negative for stem cell markers like CD34 and
CD133.17,18 (2) Cells possessing markers like CD34
and CD 133 but do not express CD14 and probably
lose CD133 and CD34 as they mature. So for the
purpose of this paper we used the term EPC to
describe any cell that has the potential to develop into
a cell expressing endothelial cell markers. At this point
we do not exclude the presence of mature endothelialcells within the circulation. These may have sloughed
off of the vessel walls. We would not expect such cells
to be useful but we cannot exclude the presence of
these cells based on this study.
Nanocomposites are materials whose components
exist at a nanometer scale. This nature allows the
resulting material to exhibit different properties from
its conventional bulk counterpart (micro-compo-
sites).19 In microcomposites phase separation between
constituents is more prominent while in nanocompo-
sites, there is increased intercalation between the
layers of the matrix or even further dispersion
uniformly within the matrix to form an exfoliated
type nanostructure.
Once formed nanocomposites exist as stacked
layers separated by an interface termed ‘interlayer’
or ‘gallery’. Depending on the ultra-structure of the
nanocomposite they are classified as follows.20 Type I:
organic polymer embedded in an inorganic matrix
without covalent bonding between the components;
type II: organic polymer embedded in an inorganic
matrix with sites of covalent bonding between the
components; type III: co-formed interpenetrating net-
works of inorganic and organic polymers without
covalent bonds between phases; type IV: co-formed
interpenetrating networks of inorganic and organic
polymers with covalent bonds between phases and
type V: non-shrinking simultaneous polymerization of
inorganic and organic polymers.
Due to the size of these nano-fillers, their surface
areas are up to 400% more than conventional
microcomposites and as such they dramatically
increase the polymer mechanical strength. We have
shown that by direct synthesis of these nanofillers into
a polymer, in this case carbonate-based polyurethanes
produce strong, bio-durable polymers.20,21 Our orig-
inal hypothesis was that by incorporation of nano-
composites into a carbonate based polyurethane a
novel class of biomaterial would be generated, which
exhibits unique biological properties previously unat-
tainable due principally to their non-linearity.20 These
properties engender amphiphilic and thermodynamic
qualities. In this study we utilised a novel type of
silica-based nanocomposite termed polyhedral oligo-
meric silsesquioxanes (POSS). We have shown that
polyurethanes containing POSS result in materials
with anti-platelet, coagulation inhibitory (heparin-like
effect) and anti-infection (bacterial adhesion and
growth prevention) properties.22
Extensive research over the last decade has been
performed on the incorporation of adhesion promot-
ing peptides into biomaterial surfaces. Since, identifi-
cation of the RGD peptide sequence as mediating the
attachment of cells to several plasma and ECMEur J Vasc Endovasc Surg Vol 32, July 2006
N. Alobaid et al.78proteins, including fibronectin and vitronectin,
researchers have been incorporating Arg-Gly-Asp
(RGD)-containing peptides on biomaterials to promote
cell attachment.23
The peptide GRGD in solution inhibits fibrinogen
binding to endothelial cells and fibrinogen-induced
endothelial cell(s) migration.23 When this peptide was
photochemically grafted to the surface of a polyethy-
lene glycol modified polyurethane (PU–PEG) to form
PU–PEG–GRGD, endothelial cell adhesion and pro-
liferation was improved. The enhancement efficiency
was correlated with GRGD content.3 In similar studies
coupling an ePTFE graft surface with RGD-containing
synthetic peptides significantly improved the endo-
thelial cell seeding of ePTFE grafts. Covalent bonding
of RGD-containing peptides based on cell-adhesive
regions of fibronectin, Arg-Gly-Asp-Ser (RGDS), and
vitronectin, Arg-Gly-Asp-Val (RGDV) to a poly-
urethane graft backbone via amide bonds enhanced
cell adhesion and proliferation.24 The GRGDVY-
grafted substrate supported a larger number of
adherent cells and a higher extent of cell spreading
than the GRGDSY-grafted substrate.9 Covalent immo-
bilization of RGD and heparin onto the surface of
polymer graft improved cell retention of EC seeding.25
To further improve this material we chose to add the
RGD motif which our work has shown results in
excellent endothelial cell adhesion and proliferation.
The RGD sequence was added as a moiety comprised
of eight peptide units.21
We tested the hypothesis that the POSS–poly(car-
bonate-urea)urethane–RGD (POSS–PCU–RGD) octa-
mer improves EPC cell adhesion and differentiation.Materials and MethodsNanocomposite synthesis of POSS–PCU–RGD
Polymer synthesis has been described in detail else-
where17 in brief; polycarbonate polyol and trans-
cyclohexanediolisobutyl-silsesquioxane were mixed
and heated to dissolve the polyhedral oligomeric
silsesquioxane (POSS) cage into the polyol component
before being cooled to 60 8C. Methylene di-isocyanate
(MDI) was added and reacted to form a pre-polymer.
Dimethylacetamide (DMAC) was then added and
103 mg of a nano-frame containing dendritic RGD
type motif as GRGDS-LA as an octomer form reacted
in at 50–60 8C for 45 min. A further 48 g of DMAC
were added slowly and the temperature adjusted to
40 8C. The pre-polymer was chain-extended by the
addition of diethylamine. Then 1-butanol in 10 g ofEur J Vasc Endovasc Surg Vol 32, July 2006DMAC was added to form a 23% (w/v) solution of
POSS–PCU solution with the POSS herein being at a
concentration of 2%. All chemicals were purchased
from Sigma Aldrich, Poole, Dorset, UK.Peptide octamer: design and synthesis
Originally developed as the multiple antigenic peptide
(MAP) system for the production of anti-peptide
antibodies, the octomer is based on a small immuno-
genically inert core of radially branching lysine
dendrites on which a number of copies of the desired
peptide is added. We have adapted the octabranching
matrix made up at three levels of lysine with eight
amino (Octavalent) terminals available for synthesiz-
ing eight copies of GRGDG peptide at the amino
terminal of the main peptide. Glycine was introduced
at the C-terminus of the main peptide to minimize any
racemization during synthesis. Incorporation of this
peptide format into the nanocomposite was adopted
rather than pendant linkages, as this promotes
stability and active conformation. Thus, two mono-
valent lysines were included, separated by a spacer
(amino–hexanoic acid) at the C-terminus of the main
peptide. The peptide was synthesized on a rink acid
resin using standard solid phase methods. The peptide
is synthesized as an acetylated fully protected peptide
except for the 23-amino groups of the two lysines at the
C-terminus which are deprotected during release from
the solid phase. The protected peptides were 95% pure
by HPLC.Isolation of peripheral blood mononuclear cells
The approval of the local ethical committee for this
study was obtained. To obtain EPC, we took blood
samples (20 ml) from consented young healthy adults,
mean ageGSD (29.3G4.7) that had no prior stimuli to
mobilise EPC from the bone marrow. Peripheral blood
mononuclear cells (PBMC) were obtained using a
modified density gradient technique (Lymphoprepe).
Briefly, 20 ml of heparinised blood was obtained from
arm vein. Lymphoprep (GlaxoSmiKline, Uxbridge, UK)
was added to the blood and centrifuged at 1500 RPM.
PBMC were isolated and washed three times with PBS
and centrifuged. The number of PBMC was counted by
two independent observers, coefficient of variation 4%.Fluorescence-activated cell sorter (FACS) analysis for CD34
In order to determine the percentage of CD34C cells in
PBMs, the PBMC fraction was incubated with 10 ml of
Nanocomposite Promotes Endothelialisation with Stem Cells 79FITC-labelled anti CD34 MAb (Miltenyi Biotec Ltd,
Bisley, Surrey, UK) for 10 min. PBMC also were
incubated with a control phycoerythrin-labelled
mouse IgG1 and FITC-labeled mouse IgG2a. Two-colour
flow cytometric analyses were performed by FACS scan.
Each analysis included more than 10,000 events.Reverse transcription polymerase chain
reaction (RT-PCR) analysis
RNA was isolated from PBMC using a Quiagen RN
easy mini kit following the manufacturer’s instruc-
tions. Cells were homogenised using a 22 gauge
needle. PCR was conducted using one step PCR
(Quiagen) RT-PCR was performed on 0.5 mM of
RNA26 and appropriately designed primer sequence.Peripheral blood mononuclear cells culture
PBMs were re-suspended in 2 ml of stem cell media
(Sigma, UK). The PBMC fraction which contained EPC
was then plated (at a density of 3!105 cells/cm2) on
dishes coated with POSS–PCU–RGD, POSS–PCU and
uncoated dishes and cultured in the presence of
vascular endothelial growth factor (VEGF; Sigma,
UK) in stem cell media (Sigma, UK). Half of the
media was changed every third days. Cells for
immunohistochemistry were cultured on slides coated
with POSS–PCU–RGD, POSS–PCU and uncoated
slides at a density of 3!105 cells/cm2.Immunofluorescence for vWF, CD31, eNOS, E-selectin
After 7 days cultured cells were immersed in a
solution containing 0.2% triton X-100 in PBS for
1 min, rinsed in PBS, and then incubated with normal
donkey serum for 30 min. Slides were incubated
with the primary anti sera over night, rinsed in
PBS, and mounted with vector shield containing 4 0,6-
diamidino-2-phenylindole (DAPI) (Sigma Aldrich,
Poole, Dorset, UK) and examined under a fluorescent
microscope. The von Willebrand factor (vWF), CD31,
E-selectin mouse antibodies were purchased from
DAKO, USA. Antibodies to endothelial nitric oxide
synthase (eNOS) (polyclonal, Rabbit) was purchased
from Santa Cruz, CA, USA.Fig. 1. A small proportion (1–2%) of PBMC expressed CD34
determined by fluorescence-activated cell sorter (FACS)
analysis.Alamar blue assay to assess cell viability and metabolism
on nanocomposites
AlamarBluee (AB) assay is a commercially available
assay (Serotec Ltd, Kidlington, Oxford, UK) which hasbeen well characterised in this laboratory as a marker
of cellular viability. AB was added to cell culture
media at a concentration of 10% (v/v). At day seven
plates were washed with 1 ml PBS and 1 ml added to
each well. After 4 h a 100 ml aliquot was removed
and the absorbance at 570 and 630 nm measured in a
96-well plate using a Multiscan MS UV visible
spectrophotometer (Labsystems, UK).Number of endothelial progenitor cells colonies
At day 7 the number of EPC colonies was counted
manually in each dish by two independent observers.
The colonies were defined morphologically as a
central core of round large cells with elongated cells
at the periphery.27,28 A central cluster of round cells
alone without associated peripheral elongated cells
was not counted as a colony. To confirm that colony
consisted of endothelial cells indirect immunostaining
of randomly selected colonies was performed with
antibodies directed towards vWF, CD 31 and eNOS.
The colonies were stained randomly. Results are
presented as a mean of numbers of colonies formed
per 106 cells plated. The cells in each experiment (in
duplicate) came from the same volunteer and the same
culture conditions.
Graph pad prism (version 3.0) was used to analyse
data throughout. Where statistical analysis is carried
out two way analysis of variance (ANOVA) was used
to compare multiple groups.Results
PBMC (1.5!107G7!105) were obtained from 20 ml of
venous blood. Flow cytometry indicated that 1–2%
of these cells expressed CD34. A representative
analysis is shown in Fig. 1. EPC are best defined as a
CD133/KDR subpopulation of CD34 cells.29 To further
characterise the harvested cells, mRNA expression for
CD34, CD133, FlK-1/KDR and CD31 were investigateEur J Vasc Endovasc Surg Vol 32, July 2006
Fig. 2. Phase-contrast micrograph of endothelial progenitor
cells (EPC) colony.
N. Alobaid et al.80by RT-PCR. The ‘house keeping’ gene GAPDH was
used as a control. Cells were shown to be positive for
these markers after isolation. They remained positive
at the end of the experiment (day 7) despite expressing
endothelial markers at this time.
Endothelial cells colony forming units comprised
clusters of round cells centrally and sprouts of spindle-
shaped cells at the periphery and these began to
appear between days 5 and day 7 on the POSS–PCU–
RGD as shown in Fig. 2. Fewer numbers of cells
became spindle shaped on POSS–PCU and uncoated
dishes. In addition, fewer numbers of EPC colonies
occurred on POSS–PCU and uncoated dishes as
compared with POSS–PCU–RGD (Fig. 3). Colonies
where identified by morphology and by staining for
endothelial lineage markers as shown in Fig. 4. The
endothelial phenotype was confirmed by immunos-
taining with antibodies specific for endothelial mar-
kers. Results are presented as a mean of numbers of
colonies formed per 106 cells plated. A representativeFig. 3. Number of endothelial progenitor cells (EPC) colonies
on polymers and uncoated dishes as control. Data are
meanGSD.
Eur J Vasc Endovasc Surg Vol 32, July 2006EPC preparation uniformly expressed CD31 on the
cell–cell membrane borders (arrows) and expressed
vWF in cytoplasmic granules (arrows), Fig. 4. In
addition, cells also expressed eNOS. E-selectin was
minimally expressed (data not shown). Similar results
were obtained in three subsequent experiments. In
each case a primary antibody free control was
produced. No staining was seen in any controls
(Fig. 4(d)). Cells were confirmed to be viable and
metabolising by the AB assay at day 7. There were no
statistical differences between the groups by AB assay
as shown in Fig. 5.Discussion
Tissue engineered cardiovascular conduits need to
have the mechanical and biological properties of
arteries in order to have superior patency rates. The
conduits need to be non-thrombogenic, have a
viscoelastic property that matches arteries and their
luminal surface should be covered with a monolayer
of endothelial cells. While the advantage of using EPC
as a source for endothelial cells is that the procedure is
much less invasive than the surgical harvest of cells
from large veins and EPC have higher proliferation
potential compared with mature ECs,30 these advan-
tages can be off-set by the time and money consuming
requirements to expand EPC and differentiate them
into mature endothelial cells in vitro before their
subsequent application.31 An alternative strategy is
to prepare a material which is inherently non-
thrombogenic, compliant and has the ability to
promote endothelialisation from EPC directly from
the blood. Previously we developed a compliant
poly(carbonate-urea)urethane (PCU) grafts which
offered greater degree of compliance match than either
ePTFE and Dacron.32 In this study, we sought to go one
step further by improving upon the luminal charac-
teristics of PCU.
As POSS acts as an amphiphile, we synthesised a
type II nanocomposite containing functional side-
group POSS molecules in the form of a pendant side-
chain attached to poly(carbonate-urea)urethane.33
This has resulted in a material that reduces both
platelet and protein adsorption known to be respon-
sible for activating coagulation. Our hypothesis is
based on the argument that the pendant nano-cage
containing silicon atoms that form foci of silicon-rich
areas with increased surface free energy,34 whilst
allowing the inorganic matrix to confer a ‘garter-like’
effect to its bulk to maintain its viscoelastic proper-
ties.32 The properties of this material make it an ideal
candidate for further studies. The incorporation of the
Fig. 4. The endothelial phenotype was confirmed by immunostaining with antibodies specific for endothelial markers, (a)
eNOS; (b) cell membrane and on cells border to border (arrow) CD31; (c) vWF contained within cytoplasmic granule (arrow);
(d) representative control sections where nuclear staining alone is visible. All cells were counterstained with DAPI showing
the nucleus as blue.
Fig. 5. AlamarBlueTM (AB) viability assay test on cells
exposed to three group on day 7. Absorbance was measured
in arbitrary units at 570 nm wavelength and background at
630 nm subtracted. Data are meanGSD.
Nanocomposite Promotes Endothelialisation with Stem Cells 81octameric GRGD biomolecule enhanced the ability of
this amphiphilic nanocomposite to serve as a bed for
stem cell attachment.
The POSS–PCU and uncoated dishes produced
significantly fewer colonies than POSS–PCU–RGD.
This demonstrates that the addition of the RGD moiety
provided a better environment for either attachment of
CD133C cells or for their differentiation. We believe
that this study demonstrates the suitability of POSS–
PCU–RGD for the in situ seeding of cardiovascular
devices in preference to POSS–PCU alone. RGD is not
selective for EPC and in theory other cells, mainly
CD14 monocytes, could attach to this surface, which
might even be beneficial since studies has shown that
these cells are proangiogenic and can mimic EPC.17
Previously we have shown that attachment of these
other cells confers antiplatelet/antithrombogenic
qualities24,35 which provides temporary benefit during
the endothelialization process. In this study, we did
not attempt to have complete monolayer of differ-
entiated endothelial cells, since exposure to flow isnecessary for the differentiation process. This study
showed over a short culture period EPC will adhere to
this new POSS–PCU biomaterial and differentiate into
cells with endothelial cell markers to indicate theEur J Vasc Endovasc Surg Vol 32, July 2006
N. Alobaid et al.82potential of this technique for endothelial regeneration
in situ.
In conclusion, we have developed a new bioactive
nanocomposite for cardiovascular applications includ-
ing the development of small diameter conduits for
coronary and vascular bypass grafts and the material
has been demonstrated in vitro to promote endothe-
lialisation from circulating EPC.Acknowledgements
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